FOXO3-mTOR metabolic cooperation in the regulation of erythroid cell maturation and homeostasis

American Journal of Hematology

Volumn 89, Issue 10, 2014, Pages 954-963

  Zhang, Xin ^a,d   Campreciós, Genís ^a   Rimmelé, Pauline ^a   Liang, Raymond ^a   Yalcin, Safak ^a   Mungamuri, Sathish Kumar ^a   Barminko, Jeffrey ^a   D'Escamard, Valentina ^a   Baron, Margaret H ^a,b   Brugnara, Carlo ^c   Papatsenko, Dmitri ^a   Rivella, Stefano ^b   Ghaffari, Saghi ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; TRANSCRIPTION FACTOR FKHRL1; FORKHEAD TRANSCRIPTION FACTOR; FOXO3 PROTEIN, MOUSE; MTOR PROTEIN, MOUSE; TARGET OF RAPAMYCIN KINASE;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BETA THALASSEMIA; BONE MARROW; CELL MATURATION; CONTROLLED STUDY; ERYTHROBLAST; ERYTHROID CELL; ERYTHROPOIESIS; GENE EXPRESSION; HOMEOSTASIS; IN VITRO STUDY; IN VIVO STUDY; METABOLIC REGULATION; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; DISEASE MODEL; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY;

ANIMALS; BETA-THALASSEMIA; DISEASE MODELS, ANIMAL; ERYTHROBLASTS; ERYTHROPOIESIS; FORKHEAD TRANSCRIPTION FACTORS; HOMEOSTASIS; MICE; MICE, KNOCKOUT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84908029999     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23786     Document Type: Article

References (74)

1. McDevitt MA, Xie J, Gordeuk V, et al. The anemia of malaria infection: Role of inflammatory cytokines. Curr Hematol Rep 2004;3:97-106.
2. Rivella S. Ineffective erythropoiesis and thalassemias. Curr Opin Hematol 2009;16:187-194.
3. Neumann CA, Krause DS, Carman CV, et al. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature 2003;424:561-565.
4. Friedman JS, Rebel VI, Derby R, et al. Absence of mitochondrial superoxide dismutase results in a murine hemolytic anemia responsive to therapy with a catalytic antioxidant. J Exp Med 2001;193:925-934.
5. Marinkovic D, Zhang X, Yalcin S, et al. Foxo3 is required for the regulation of oxidative stress in erythropoiesis. J Clin Invest 2007;117:2133-2144.
6. Yu D, dos Santos CO, Zhao G, et al. miR-451 protects against erythroid oxidant stress by repressing 14-3-3zeta. Genes Dev 2010;24:1620-1633.
7. Kong Y, Zhou S, Kihm AJ, et al. Loss of alpha-hemoglobin-stabilizing protein impairs erythropoiesis and exacerbates beta-thalassemia. J Clin Invest 2004;114:1457-1466.
8. Valentine WN. Metabolism of human erythrocytes. Studies in health and disease. Arch Intern Med 1975;135:1307-1313.
9. Bossi D, Giardina B. Red cell physiology. Mol Aspects Med 1996;17:117-128.
10. Nijhof W, Wierenga PK, Staal GE, et al. Changes in activities and isozyme patterns of glycolytic enzymes during erythroid differentiation in vitro. Blood 1984;64:607-613.
11. Kim HD, Koury MJ, Lee SJ, et al. Metabolic adaptation during erythropoietin-mediated terminal differentiation of mouse erythroid cells. Blood 1991;77:387-392.
12. Nemoto S, Finkel T. Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway. Science 2002;295:2450-2452.
13. Kops GJ, Dansen TB, Polderman PE, et al. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 2002;419:316-321.
14. Zhang X, Rielland M, Yalcin S, et al. Regulation and function of FoxO transcription factors in normal and cancer stem cells: What have we learned? Curr Drug Targets 2011;12:1267-1283.
15. van den Berg MC, Burgering BM. Integrating opposing signals toward forkhead box O. Antioxid Redox Signal 2011;14:607-621.
16. Kashii Y, Uchida M, Kirito K, et al. A member of Forkhead family transcription factor, FKHRL1, is one of the downstream molecules of phosphatidylinositol 3-kinase-Akt activation pathway in erythropoietin signal transduction. Blood 2000;96:941-949.
17. Uddin S, Kottegoda S, Stigger D, et al. Activation of the Akt/FKHRL1 pathway mediates the antiapoptotic effects of erythropoietin in primary human erythroid progenitors. Biochem Biophys Res Commun 2000;275:16-19.
18. Ghaffari S, Jagani Z, Kitidis C, et al. Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor. Proc Natl Acad Sci USA 2003;100:6523-6528.
19. Bakker WJ, Blazquez-Domingo M, Kolbus A, et al. FoxO3a regulates erythroid differentiation and induces BTG1, an activator of protein arginine methyl transferase 1. J Cell Biol 2004;164:175-184.
20. Bakker WJ, van Dijk TB, Parren-van Amelsvoort M, et al. Differential regulation of Foxo3a target genes in erythropoiesis. Mol Cell Biol 2007;27:3839-3854.
21. Franco SS, De Falco L, Ghaffari S, et al. Resveratrol accelerates erythroid maturation by activation of FoxO3 and ameliorates anemia in beta-thalassemic mice. Haematologica 2014;99:267-275.
22. Pourfarzad F, von Lindern M, Azarkeivan A, et al. Hydroxyurea responsiveness in beta-thalassemic patients is determined by the stress response adaptation of erythroid progenitors and their differentiation propensity. Haematologica 2013;98:696-704.
23. van der Vos KE, Eliasson P, Proikas-Cezanne T, et al. Modulation of glutamine metabolism by the PI(3)K-PKB-FOXO network regulates autophagy. Nat Cell Biol 2012;14:829-837.
24. Rimmele P, d'Esamard V, Fatih K, et al. Metabolic cross talk between Foxo3 and mTOR is essential for hematopoietic stem cell function. Blood 2012;120:a856.
25. Warr MR, Binnewies M, Flach J, et al. FOXO3A directs a protective autophagy program in haematopoietic stem cells. Nature 2013.
26. Sandri M, Sandri C, Gilbert A, et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004;117:399-412.
27. Yeo H, Lyssiotis CA, Zhang Y, et al. FoxO3 coordinates metabolic pathways to maintain redox balance in neural stem cells. EMBO J 2013;32:2589-2602.
28. Camprecios G, Barminko J, Bernitz J, et al. Steady state differences in metabolic properties of bone marrow versus spleen erythroid cells. Blood 2013;122:943a.
29. Rimmele P, Bigarella C, Liang R, et al. Aging-like phenotype and defective lineage specification in SIRT1-deficient hematopoietic stem and progenitor cells. Stem Cell Rep 2014 (in press) 3:1-16.
30. Kadri Z, Maouche-Chretien L, Rooke HM, et al. Phosphatidylinositol 3-kinase/Akt induced by erythropoietin renders the erythroid differentiation factor GATA-1 competent for TIMP-1 gene transactivation. Mol Cell Biol 2005;25:7412-7422.
31. Hammerman PS, Fox CJ, Birnbaum MJ, et al. Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival. Blood 2005;105:4477-4483.
32. Ghaffari S, Kitidis C, Zhao W, et al. AKT induces erythroid-cell maturation of JAK2-deficient fetal liver progenitor cells and is required for Epo regulation of erythroid-cell differentiation. Blood 2006;107:1888-1891.
33. Zhao W, Kitidis C, Fleming MD, et al. Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway. Blood 2006;107:907-915.
34. Howell JJ, Manning BD. mTOR couples cellular nutrient sensing to organismal metabolic homeostasis. Trends Endocrinol Metab 2011;22:94-102.
35. Zoncu R, Efeyan A, Sabatini DM. mTOR: From growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011;12:21-35.
36. Grech G, Blazquez-Domingo M, Kolbus A, et al. Igbp1 is part of a positive feedback loop in stem cell factor-dependent, selective mRNA translation initiation inhibiting erythroid differentiation. Blood 2008;112:2750-2760.
37. Geslain R, Uddin S, Liu H, et al. Distinct functions of erythropoietin and stem cell factor are linked to activation of mTOR kinase signaling pathway in human erythroid progenitors. Cytokine 2013;61:329-335.
38. Diekmann F, Rovira J, Diaz-Ricart M, et al. mTOR inhibition and erythropoiesis: Microcytosis or anaemia? Nephrol Dial Transplant 2012;27:537-541.
39. Fishbane S, Cohen DJ, Coyne DW, et al. Posttransplant anemia: The role of sirolimus. Kidney Int 2009;76:376-382.
40. Castrillon DH, Miao L, Kollipara R, et al. Suppression of ovarian follicle activation in mice by the transcription factor Foxo3a. Science 2003;301:215-218.
41. Yalcin S, Zhang X, Luciano JP, et al. Foxo3 is essential for the regulation of ataxia telangiectasia mutated and oxidative stress-mediated homeostasis of hematopoietic stem cells. J Biol Chem 2008;283:25692-25705.
42. -/-) hematopoietic progenitors. Blood 2001;98:2948-2957.
43. England SJ, McGrath KE, Frame JM, et al. Immature erythroblasts with extensive ex vivo self-renewal capacity emerge from the early mammalian fetus. Blood 2011;117:2708-2717.
44. Chen K, Liu J, Heck S, et al. Resolving the distinct stages in erythroid differentiation based on dynamic changes in membrane protein expression during erythropoiesis. Proc Natl Acad Sci USA 2009;106:17413-17418.
45. Yalcin S, Marinkovic D, Mungamuri SK, et al. ROS-mediated amplification of AKT/mTOR signalling pathway leads to myeloproliferative syndrome in Foxo3(-/-) mice. EMBO J 2010;29:4118-4131.
46. Zhang X, Yalcin S, Lee DF, et al. FOXO1 is an essential regulator of pluripotency in human embryonic stem cells. Nat Cell Biol 2011;13:1092-1099.
47. Liang R, Ghaffari S. Stem cells, redox signaling, and stem cell aging. Antioxid Redox Signal 2014;20:1902-1916.
48. Sarbassov DD, Sabatini DM. Redox regulation of the nutrient-sensitive raptor-mTOR pathway and complex. J Biol Chem 2005;280:39505-39509.
49. Yoshida S, Hong S, Suzuki T, et al. Redox regulates mammalian target of rapamycin complex 1 (mTORC1) activity by modulating the TSC1/TSC2-Rheb GTPase pathway. J Biol Chem 2011;286:32651-32660.
50. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009;10:307-318.
51. Gregory CJ. Erythropoietin sensitivity as a differentiation marker in the hemopoietic system: Studies of three erythropoietic colony responses in culture. J Cell Physiol 1976;89:289-301.
52. Ramos P, Casu C, Gardenghi S, et al. Macrophages support pathological erythropoiesis in polycythemia vera and beta-thalassemia. Nat Med 2013;19:437-445.
53. Hashimoto D, Chow A, Noizat C, et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity 2013;38:792-804.
54. Rivella S. The role of ineffective erythropoiesis in non-transfusion-dependent thalassemia. Blood Rev 2012;26 Suppl 1:S12-S15.
55. Libani IV, Guy EC, Melchiori L, et al. Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia. Blood 2008;112:875-885.
56. Peslak SA, Wenger J, Bemis JC, et al. EPO-mediated expansion of late-stage erythroid progenitors in the bone marrow initiates recovery from sublethal radiation stress. Blood 2012;120:2501-2511.
57. Dev A, Fang J, Sathyanarayana P, et al. During EPO or anemia challenge, erythroid progenitor cells transit through a selectively expandable proerythroblast pool. Blood 2010;116:5334-5346.
58. Chen CC, Jeon SM, Bhaskar PT, et al. FoxOs inhibit mTORC1 and activate Akt by inducing the expression of Sestrin3 and Rictor. Dev Cell 2010;18:592-604.
59. Khatri S, Yepiskoposyan H, Gallo CA, et al. FOXO3a regulates glycolysis via transcriptional control of tumor suppressor TSC1. J Biol Chem 2010;285:15960-15965.
60. Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004;14:1296-1302.
61. Guertin DA, Stevens DM, Thoreen CC, et al. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell 2006;11:859-871.
62. Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307:1098-1101.
63. Efeyan A, Zoncu R, Sabatini DM. Amino acids and mTORC1: From lysosomes to disease. Trends Mol Med 2012;18:524-533.
64. Thein SL. Genetic modifiers of beta-thalassemia. Haematologica 2005;90:649-660.
65. Yeo H, Lyssiotis CA, Zhang Y, et al. FoxO3 coordinates metabolic pathways to maintain redox balance in neural stem cells. EMBO J 2013;32:2589-2602.
66. Shinar E, Rachmilewitz EA. Oxidative denaturation of red blood cells in thalassemia. Semin Hematol 1990;27:70-82.
67. Scott MD, Eaton JW. Thalassaemic erythrocytes: Cellular suicide arising from iron and glutathione-dependent oxidation reactions? Br J Haematol 1995;91:811-819.
68. Fibach E, Bianchi N, Borgatti M, et al. Effects of rapamycin on accumulation of alpha-, beta- and gamma-globin mRNAs in erythroid precursor cells from beta-thalassaemia patients. Eur J Haematol 2006;77:437-441.
69. Bayeva M, Khechaduri A, Puig S, et al. mTOR regulates cellular iron homeostasis through tristetraprolin. Cell Metab 2012;16:645-657.
70. Marty C, Lacout C, Droin N, et al. A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression. Leukemia 2013;27:2187-2195.
71. Duhe RJ, Evans GA, Erwin RA, et al. Nitric oxide and thiol redox regulation of Janus kinase activity. Proc Natl Acad Sci USA 1998;95:126-131.
72. Maziere C, Conte MA, Maziere JC. Activation of JAK2 by the oxidative stress generated with oxidized low-density lipoprotein. Free Radic Biol Med 2001;31:1334-1340.
73. Nieborowska-Skorska M, Kopinski PK, Ray R, et al. Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood 2012;119:4253-4263.
74. Walz C, Crowley BJ, Hudon HE, et al. Activated JAK2 with the V617F point mutation promotes G1/S-phase transition. J Biol Chem 2006;281:18177-18183.